Table 1.

Study subjects.

Characteristic	Noninflammatory Controls	CTD Controls	JIA Controls	ERA	p
N	6	9	17	9	—
Age, yrs^†	3.8 (3.0–9.6)	11 (8.0–14)	6.2 (2.8–11)	12 (9.5–14)	0.014
Female, %	67	56	82	0	0.001
Ethnicity, %					0.070
Latino	17	56	12	0
Non-Latino White	67	33	82	67
African American	17	0	6	22
Other	0	11	0	11
Treatment, %
NSAID	33	0	65	56	0.013
Systemic corticosteroid	0	33	0	11	0.042
Methotrexate	0	78	65	56	0.019
Etanercept	0	0	5.9	33	0.055
Other DMARD^*	0	33	0	0	0.009
Active disease	0	67	100	78	< 0.001
GI symptoms,%	0	0	5.9	22	0.242
Fecal calprotectin, μg/g (range)^†	80 (28–120)	26 (0–38)	51 (36–98)	171 (34–280)	0.034
Fecal calprotectin, > 120 μg/g, %	17	11	18	67	0.024

↵† Continuous data are presented as medians (intraquartile range).
↵* One patient was taking mycophenolate, another was taking both mycophenolate and hydroxychloroquine, and a third was taking 6-mercaptopurine. DMARD: disease-modifying antirheumatic drug; CTD: connective tissue disease; ERA: enthesis-related arthritis.